Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Synthesis . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel chiral resolution method using aspartic acid eliminates chromatography, offering high purity and scalable production for pharmaceutical intermediates.
Novel patent CN121108124A offers high-purity Fezolinetant intermediate synthesis. Mild conditions and readily available materials ensure supply chain reliability and cost efficiency for pharmaceutical manufacturing.
Patent CN102040594A introduces a recyclable chiral bisoxazoline ligand with imidazolium salts, offering superior enantioselectivity and stability for pharmaceutical intermediate manufacturing.
Novel quinoline-substituted bisoxazoline ligand enables high enantioselectivity in trifluoromethylation. Offers scalable synthesis and cost-effective supply chain solutions for pharmaceutical intermediates.
Novel patent CN110183445A offers chiral-resolution-free synthesis for Moxifloxacin intermediates, ensuring high purity and supply chain stability for global pharmaceutical manufacturers.
Novel chiral induction method for Paxlovid intermediate. Reduces cost and improves safety. Reliable supply chain partner for pharmaceutical manufacturing.
Novel Pd-catalyzed synthesis offers high enantioselectivity. Reduces costs and improves supply chain reliability for pharmaceutical intermediates.
Patent CN114057717B reveals novel ligand synthesis enhancing enantioselectivity. Delivers substantial cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Novel synthesis method for high-purity chiral intermediates. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Discover novel axial chiral oxindole-derived styrene phosphine catalysts from patent CN111777637B. Enables asymmetric cyclization with mild conditions and scalable synthesis for fine chemical manufacturing.
Novel oxindole-derived styrene phosphine catalysts enabling high-yield asymmetric cyclizations with mild conditions for fine chemical manufacturing.
Patent CN102516300A discloses efficient phosphine ligands enabling superior enantioselectivity and simplified synthesis for cost-effective pharmaceutical intermediate manufacturing.
Patent CN112920053B details a mild, high-yield route for chiral amines used in asthma and oncology drugs, offering significant supply chain stability.
Patent CN115490626B reveals a high-purity chiral intermediate route for PF-07321332. This method offers significant cost reduction and supply chain reliability for antiviral manufacturing.
Patent CN118878543A reveals high-purity axial chiral synthesis. Delivers significant cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Patent CN114315866B enables eco-friendly levamisole hydrochloride production via L-mandelic acid route eliminating chiral catalysts and reducing waste for enhanced supply chain resilience.
Discover a cost-effective, high-yield synthesis for Sacubitril intermediates with >99% purity and >98% ee, eliminating isomer impurities and supply chain risks.
Discover how this novel chiral catalyst enables 99% ee synthesis with 90% yield, reducing R&D costs and supply chain risks for oncology drug development.
Solve chiral drug synthesis challenges with metal-free catalysis. Achieve >99% ee, mild conditions, and scalable production for pharmaceutical intermediates. Reduce costs and supply chain risks.
Discover efficient chiral indolo-dihydropyridoindole synthesis with 96% yield and 95% ee. Ideal for pharmaceutical R&D and cancer drug development. Scale up with CDMO expertise.